Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cybin Inc
(NY:
CYBN
)
10.60
UNCHANGED
Streaming Delayed Price
Updated: 8:00 PM EST, Nov 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
10.60
Bid (Size)
11.12 (10)
Ask (Size)
11.36 (3)
Prev. Close
10.60
Today's Range
10.60 - 10.60
52wk Range
6.500 - 21.66
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports Sustained 12-Month Efficacy for CYB003 in Treating Major Depressive Disorder
November 18, 2024
Via
Investor Brand Network
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
November 18, 2024
From
Cybin Inc.
Via
Business Wire
Performance
YTD
-30.26%
-30.26%
1 Month
-2.93%
-2.93%
3 Month
+5.26%
+5.26%
6 Month
-20.53%
-20.53%
1 Year
-38.22%
-38.22%
More News
Read More
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present Key 12-Month Data and Phase 3 Program Insights for CYB003 in Upcoming Webcast
November 14, 2024
Via
Investor Brand Network
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
November 14, 2024
From
Cybin Inc.
Via
Business Wire
Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression
November 13, 2024
Via
Benzinga
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
November 13, 2024
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Begins Phase 3 Trials of CYB003 for Depression, Building on Promising Phase 2 Results
November 13, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Present Advancements in Mental Health Treatment at Milken Institute Summit
October 31, 2024
Via
Investor Brand Network
Cybin to Participate at the 2024 Milken Institute Future of Health Summit
October 31, 2024
From
Cybin Inc.
Via
Business Wire
BioMedNewsBreaks — Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Granted Patent for Lead Candidates in CYB005 Program
October 24, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
October 24, 2024
From
Cybin Inc.
Via
Business Wire
EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program
October 24, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate in Upcoming Water Tower Research Fireside Chat
October 03, 2024
Via
Investor Brand Network
Exposures
Product Safety
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024
October 03, 2024
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Strengthens Its Clinical Development Team
October 01, 2024
Via
Investor Brand Network
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
October 01, 2024
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Chief Medical Officer to Participate in a Panel Discussion at Upcoming Summit
September 24, 2024
Via
Investor Brand Network
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
September 24, 2024
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports on Status of Key Clinical Milestones
September 20, 2024
Via
Investor Brand Network
Cybin Provides Corporate Update on Upcoming Clinical Milestones
September 19, 2024
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Completes 38-for-1 Share Consolidation
September 19, 2024
Via
Investor Brand Network
Cybin Announces Completion of Previously Announced Share Consolidation
September 19, 2024
From
Cybin Inc.
Via
Business Wire
Leadership Shake-Ups In Cannabis And Psychedelics: Maryland's Cannabis Chief Resigns, Costly Legal Battle In MA Drags On & More
September 06, 2024
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
Via
Investor Brand Network
Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
From
Cybin Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.